News for week ending 24 May 2002
NEW GLIVEC STUDY RESULTS
A new study shows Glivec is three times more effective than current first-line treatment for Chronic Myeloid Leukaemia (CML).
The American study compared Glivec to Interferon Combination Therapy, and found it is nearly three times more effective, and significantly delays the progression to the advanced stages of CML.
Following these results, Novartis will soon submit an application to health authorities globally for the use of Glivec as first line treatment in CML.
Back to welcome page
Back to news archives
Complete this month's questionnaire to qualify for extra Continuing Education credits. Click here For the answers to last month's quiz click here.
Click here to find out who the winners are for the Pharmacy Today/Zuellig Pharma Pharmacy Awards 2002. Also view and purchase photos of the Awards.
For the leading stories in our latest issue of Pharmacy Today magazine visit our welcome page.
To subscribe to Pharmacy Today, or to purchase The Beauty Manual or The Pharmacy Healthcare Handbook click here.
Consumer Health Information
New Zealand Doctor Online
Home II Conferences II Contact Us II Continuing Education II Magazine Profile II Monthly News Archives
Weekly News Archives II II Readership II Search Magazine Archives II Submit a Classified Advertisement